Table 1. Correlation between clinicopathological parameters and SLC2A1 expression in 279 gastric cancer patients (Eulji Hospital cohort).
| Parameters | N = 279 | SLC2A1 expression | P-value | |
|---|---|---|---|---|
| Low (n = 135), % | High (n = 144), % | |||
| Age (year) | ||||
| <65 | 84 | 45 (33.3) | 39 (27.1) | 0.2551 |
| ≥65 | 195 | 90 (66.7) | 105 (72.9) | |
| Sex | ||||
| Male | 179 | 87 (64.4) | 92 (63.9) | 0.9231 |
| Female | 100 | 48 (35.6) | 52(36.1) | |
| T stage | ||||
| 1 | 158 | 92 (68.1) | 66 (45.8) | <0.0012 |
| 2 | 21 | 10 (7.4) | 11 (7.6) | |
| 3 | 52 | 18 (13.3) | 34 (23.6) | |
| 4 | 48 | 15 (11.1) | 33 (22.9) | |
| N stage | ||||
| 0 | 177 | 101 (74.8) | 76 (52.8) | <0.0012 |
| 1 | 25 | 12 (8.9) | 13 (9.0) | |
| 2 | 21 | 4 (3.0) | 17 (11.8) | |
| 3 | 56 | 18 (13.3) | 38 (26.4) | |
| Location | ||||
| Cardia, fundus body | 102 | 55 (40.7) | 47 (32.6) | 0.161 |
| Antrum or pylorus | 177 | 80 (59.3) | 97 (67.4) | |
| Size | ||||
| ≤ 3 cm | 123 | 72 (53.3) | 51 (35.4) | 0.0031 |
| > 3 cm | 156 | 63 (46.7) | 93 (64.6) | |
| Lauren type | ||||
| Intestinal | 175 | 72 (53.3) | 103 (71.5) | 0.0023 |
| Diffuse | 61 | 46 (34.1) | 15 (10.4) | |
| Mixed | 43 | 17 (12.6) | 26 (18.1) | |
| Histological grade | ||||
| Well differentiated | 41 | 24 (17.8) | 17 (11.8) | <0.0014 |
| Moderately differentiated | 117 | 37 (27.4) | 80 (55.6) | |
| Poorly differentiated | 54 | 26 (19.3) | 28 (19.4) | |
| Signet ring5 | 67 | 48 (35.6) | 19 (13.2) | |
| Lymphatic invasion | ||||
| Not identified | 155 | 92 (68.1) | 63 (43.8) | <0.0011 |
| Present | 124 | 43 (31.9) | 81 (56.2) | |
| Vascular invasion | ||||
| Not identified | 233 | 127 (94.1) | 106 (73.6) | <0.0011 |
| Present | 46 | 8 (5.9) | 38 (26.4) | |
| Perineural invasion | ||||
| Not identified | 223 | 113 (83.7) | 110 (76.4) | 0.1271 |
| Present | 56 | 22 (16.3) | 34 (23.6) | |
| Epstein-Barr Virus | ||||
| Absent | 242 | 121 (89.6) | 121 (84.0) | 0.1681 |
| Present | 37 | 14 (10.4) | 23 (16.0) | |
| HER2 | ||||
| Negative | 257 | 125 (98.4) | 132 (95.7) | 0.2855 |
| Positive | 8 | 2 (1.6) | 6 (4.3) | |
| PD-L1 | ||||
| Negative | 189 | 100 (74.1) | 89 (61.8) | 0.0281 |
| Positive | 90 | 35 (25.9) | 55 (38.2) | |
| Prognostic nutritional index | 52.56 ± 1.4 | 49.13 ± 1.04 | 0.0486 | |
| Adjuvant chemotherapy7 | ||||
| Sensitive | 121 | 67 (90.5) | 54 (70.1) | 0.002 |
| Resistant | 30 | 7 (9.5) | 23 (29.9) | |
HER2, human epidermal growth factor receptor 2; PD-L1, programmed death-ligand 1.
1 χ2 test.
2 linear-by-linear association test.
3 intestinal type versus diffuse or mixed type.
4 well or moderately differentiated type versus poorly differentiated or signet ring type.
5 Fisher’s exact test.
6 Student’s t-test.
7 One hundred fifty-one patients with postoperative adjuvant chemotherapy.
p < 0.05 is shown in bold.